Metabolon Signs Collaboration with Army Medical Research Institute
Metabolon, Inc., the leader in metabolomics-driven biomarker discovery, announced today the signing of a contract supporting the US Army Medical Research Institute of Infectious Diseases (USAMRIID). The collaboration uses Metabolon's proprietary metabolomics platform to study the biochemical profiles of humans given the AVA anthrax vaccine. The AVA vaccine is the only FDA-licensed anthrax vaccine for humans.
"This collaboration represents the first large-scale metabolomics study of human subjects given a vaccine," said Mike Milburn, Metabolon's Chief Scientific Officer. "This type of comprehensive biochemical profiling will help USAMRIID better understand the vaccine's safety, efficacy, and mechanism of action."
About Metabolon
Metabolon is the industry leader in the discovery of biomarkers through the use of metabolomics, a powerful scientific approach for the discovery and development of drugs and the early diagnosis of disease. Metabolon's patented technology dramatically impacts drug discovery and development processes by accurately measuring the spectrum of biochemical changes and mapping these changes to metabolic pathways. Metabolon's technology can identify safer compounds for development, shorten a drug's time to market and identify novel biomarkers for earlier disease detection. In 2006, Metabolon was awarded a patent that broadly covers the metabolomic methods used to identify biomarkers seen in patients with amyotrophic lateral sclerosis (ALS).
About USAMRIID
USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.
The information contained in this press release does not necessarily reflect the position or the policy of the United States government and no official endorsement should be inferred.